GLOBAL BLASTOCYST VITRIFICATION KIT & VITRIFICATION THAWING KIT - BASED ON S3

K092963 · Genx Intl., Inc. · MQL · Jan 14, 2011 · Obstetrics/Gynecology

Device Facts

• Record ID: K092963
• Device Name: GLOBAL BLASTOCYST VITRIFICATION KIT & VITRIFICATION THAWING KIT - BASED ON S3
• Applicant: Genx Intl., Inc.
• Product Code: MQL · Obstetrics/Gynecology
• Decision Date: Jan 14, 2011
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 884.6180
• Device Class: Class 2

Intended Use

global® Blastocyst Fast Freeze Kit - Based on S3: Media Intended for cryopreservation of human blastocysts. global® Blastocyst Fast Freeze Thawing Kit - Based on S3: Media intended for the thawing and recovery of human blastocysts that have been cryopreserved using the global® Blastocyst Fast Freeze Kit - Based on S3.

Device Story

The global® Blastocyst Fast Freeze Kit and global® Blastocyst Fast Freeze Thawing Kit are reproductive media used in clinical laboratory settings. The freezing kit facilitates the cryopreservation of human blastocysts, while the thawing kit enables the recovery of these blastocysts post-cryopreservation. These media are intended for use by trained embryologists in assisted reproductive technology (ART) procedures. The kits provide the necessary chemical environment to maintain blastocyst viability during the freezing and thawing processes, supporting subsequent clinical decision-making regarding embryo transfer.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Reproductive media and supplements for cryopreservation and thawing of human blastocysts. Classified under 21 CFR 884.6180, Product Code MOL. The device consists of chemical media formulations.

Indications for Use

Indicated for the cryopreservation, thawing, and recovery of human blastocysts.

Regulatory Classification

Identification

Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).

Special Controls

*Classification.* Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo is a circular seal with the department's name around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines.

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

Mr. Michael D. Cecchi President GenX International, Inc. 393 Soundview Road GUILFORD CT 06437

JAN 1 4 201

Re: K092963

Trade Name: global® Blastocyst Fast Freeze Kit - Based on S3 global® Blastocyst Fast Freeze Thawing Kit - Based on So Regulation Number: 21 CFR \$884.6180 Regulation Name: Reproductive media and supplements Regulatory Class: II Product Code: MOL Dated: January 7, 2011 Received: January 12, 2011

Dear Mr. Cecchi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regilations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related

{1}------------------------------------------------

adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default:htm.

Sincerely yours,

Herbert Lemmer MD

Herbert P. Lerner, M.D., Director (Acting) Division of Reproductive, Gastro-Renal and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health .

Enclosure

{2}------------------------------------------------

<genX> international, inc. 510(K) Submission (K092963)

## Indications for Use

510 (k) Number (if known) K092963

8-global® Blastocyst Fast Freeze Kit - Based on S3:

- Media Intended for cryopreservation of human blastocysts. .
12-global® Blastocyst Fast Freeze Thawing Kit - Based on S3

- Media intended for the thawing and recovery of human blastocysts that . have been cryopreserved using the &-global® Blastocyst Fast Freeze Kit - Based on \$3.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

or

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use_X

Over-the Counter Use

Tony B. Why

B